| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 8, 2012Eisai Recognizes Inaugural LGS Awareness Day and Epilepsy Awareness Month with Launch of New Caregiver Support Video
With approximately two million people in the United States living with epilepsy, including a severe and rare form called Lennox-Gastaut syndrome...
-
Oct 22, 2012-- FYCOMPA is the First FDA-Approved Non-competitive AMPA Glutamate Receptor Antagonist --
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved FYCOMPA (perampanel) as an adjunctive treatment for...
-
Aug 20, 2012
Eisai Inc. announced today that the results of two studies: "Evaluation of Adjunctive Perampanel in Patients with Refractory Partial Onset...
-
Jul 30, 2012Eisai Plans to Submit Applications for Marketing Approval throughout the Americas
WOODCLIFF LAKE, NJ, and SAN DIEGO, CA, July 30, 2012 -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Arena has transferred the BELVIQ® (lorcaserin hydrochloride)...
-
Jul 25, 2012
Eisai Inc. announced today that the results of the study, "Adjunctive Perampanel For Refractory Partial-Onset Seizures: Randomized Phase III...
